Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 11/20 | 0.69 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.69 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.44 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.44 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.44 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139511 | 0.94 | MAPK14 (0.72) | MAPK13MAPK12MAPK11MAPK14CSNK1D | |
| SCHEMBL16566742 | 0.94 | MAPK14 (0.72) | MAPK13MAPK12MAPK11MAPK14CSNK1D | |
| SCHEMBL13819548 | 0.94 | MAPK14 (0.72) | MAPK13MAPK12MAPK11MAPK14CSNK1D | |
| SCHEMBL5139505 | 0.91 | MAPK14 (0.69) | MAPK13MAPK12MAPK11MAPK14CSNK1D | |
| SCHEMBL5769752 | 0.90 | MAPK13 (0.68) | MAPK13MAPK12MAPK11MAPK14CSNK1D | |
| SCHEMBL5768584 | 0.87 | MAPK14 (0.82) | MAPK13MAPK12MAPK11MAPK14CSNK1D | |
| SCHEMBL5771409 | 0.87 | MAPK14 (0.72) | MAPK13MAPK12MAPK11MAPK14CSNK1D | |
| SCHEMBL5138790 | 0.86 | MAPK14 (0.66) | MAPK13MAPK12MAPK11MAPK14CSNK1D | |
| SCHEMBL5139512 | 0.86 | MAPK13 (0.72) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5770878 | 0.85 | MAPK14 (0.72) | MAPK13MAPK12MAPK11MAPK14CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242273-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8242273-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8124765-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-28 | — | — | US | disclosed |
| US-8124765-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-28 | — | — | US | disclosed |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-7807832-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| US-7807832-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| WO-2007016286-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | DCK, DPYD, DTYMK | MAPK13 1862/4885MAPK12 1311/4885MAPK11 2543/4885 |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DCK, DPYD, DTYMK | MAPK13 1862/4885MAPK12 1311/4885MAPK11 2543/4885 |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DCK, DPYD, DTYMK | MAPK13 1862/4885MAPK12 1311/4885MAPK11 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.